A systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disorders

Abdel-Baki, 2012, Pharmacotherapy challenges in patients with first-episode psychosis, Journal of Affective Disorders, 138, S3, 10.1016/j.jad.2012.02.029 Acosta, 2009, Evaluation of noncompliance in schizophrenia patients using electronic monitoring (MEMS®) and its relationship to sociodemographic, clinical and psychopathological variables, Schizophrenia Research, 107, 213, 10.1016/j.schres.2008.09.007 Amador, 1993, Assessment of insight in psychosis, American Journal of Psychiatry, 150, 873, 10.1176/ajp.150.6.873 Anderson, 2010, An exploratory, randomized controlled trial of adherence therapy for people with schizophrenia, International Journal of Mental Health Nursing, 19, 340, 10.1111/j.1447-0349.2010.00681.x Andreasen, 1984 Andreasen, 1989 Arana, 2000, An overview of side effects caused by typical antipsychotics, Journal of Clinical Psychiatry, 61, S5 1987 Baloush-Kleinman, 2011, Adherence to antipsychotic drug treatment in early-episode schizophrenia: a six-month naturalistic follow-up study, Schizophrenia Research, 130, 176, 10.1016/j.schres.2011.04.030 Barkhof, 2012, Interventions to improve adherence to antipsychotic medication in patients with schizophrenia—a review of the past decade, European Psychiatry, 27, 9, 10.1016/j.eurpsy.2011.02.005 Barnes, 1989, A rating scale for drug-induced akathisia, British Journal of Psychiatry, 154, 672, 10.1192/bjp.154.5.672 Barnes, 2009, Antipsychotic long-acting injections: prescribing practice in the UK, British Journal of Psychiatry, 195, S37, 10.1192/bjp.195.52.s37 Baumann, 2004, The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry, Pharmacopsychiatry, 37, 243, 10.1055/s-2004-832687 Beck, 2011, Are we addressing the ‘right stuff’ to enhance adherence in schizophrenia? Understanding the role of insight and attitudes towards medication, Schizophrenia Research, 132, 42, 10.1016/j.schres.2011.07.019 Becker, 1993, A new patient focused index for measuring quality of life in persons with severe and persistent mental illness, Quality of Life Research, 2, 239, 10.1007/BF00434796 Bhanji, 2004, A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia, European Neuropsychopharmacology, 14, 87, 10.1016/S0924-977X(03)00109-3 Birchwood, 1994, A self-report insight scale for psychosis: reliability, validity and sensitivity to change, Acta Psychiatrica Scandinavica, 89, 62, 10.1111/j.1600-0447.1994.tb01487.x Buchanan, 1992, A two-year prospective study of treatment compliance in patients with schizophrenia, Psychological Medicine, 22, 787, 10.1017/S0033291700038228 Budd, 1996, Health beliefs and compliance with antipsychotic medication, British Journal of Clinical Psychology, 35, 393, 10.1111/j.2044-8260.1996.tb01193.x Byerly, 2005, A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia, Psychiatry Research, 133, 129, 10.1016/j.psychres.2004.11.002 Byerly, 2008, The brief adherence rating scale (BARS) validated against electronic monitoring in assessing the antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder, Schizophrenia Research, 100, 60, 10.1016/j.schres.2007.12.470 Cannon-Spoor, 1982, Measurement of premorbid adjustment in chronic schizophrenia, Schizophrenia Bulletin, 8, 470, 10.1093/schbul/8.3.470 Caseiro, 2012, Predicting relapse after a first episode of non-affective psychosis: a three-year follow-up study, Journal of Psychiatric Research, 46, 1099, 10.1016/j.jpsychires.2012.05.001 Chakos, 2001, Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials, The American Journal of Psychiatry, 158, 518, 10.1176/appi.ajp.158.4.518 Chisholm, 2000, Client socio-demographic and service receipt inventory—European version: development of an instrument for international research. Epsilon study 5. European psychiatric services: inputs linked to outcome domains and needs, British Journal of Psychiatry, 177, S28, 10.1192/bjp.177.39.s28 Chouinard, 2005, Manual for the extrapyramidal symptom rating scale (ESRS), Schizophrenia Research, 76, 247, 10.1016/j.schres.2005.02.013 Coldham, 2002, Medication adherence of individuals with a first episode of psychosis, Acta Psychiatrica Scandinavica, 106, 286, 10.1034/j.1600-0447.2002.02437.x David, 1990, Insight and psychosis, British Journal of Psychiatry, 156, 798, 10.1192/bjp.156.6.798 Day, 1995, A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients, British Journal of Psychiatry, 166, 650, 10.1192/bjp.166.5.650 Day, 2005, Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals, Archives of General Psychiatry, 62, 717, 10.1001/archpsyc.62.7.717 De Hert, 2012, Metabolic and cardiovascular adverse effects associated with antipsychotic drugs, Nature Reviews Endocrinology, 8, 114, 10.1038/nrendo.2011.156 Delis, 1988, Integrating clinical assessment with cognitive neuroscience: construct validation of the california verbal learning test, Journal of Consulting and Clinical Psychology, 56, 123, 10.1037/0022-006X.56.1.123 Delis, 2004, Reliability and validity of the delis-kaplan executive function system: an update, Journal of the International Neuropsychological Society, 10, 301, 10.1017/S1355617704102191 Diaz, 2004, Adherence to conventional and atypical antipsychotics after hospital discharge, Journal of Clinical Psychiatry, 65, 354, 10.4088/JCP.v65n0311 Eker, 1995, Perceived social support: psychometric properties of the MSPSS in normal and pathological groups in a developing country, Social Psychiatry Psychiatric Epidemiology, 30, 121, 10.1007/BF00802040 Elliott, 2005, Cost-effectiveness of adherence-enhancing interventions: A quality assessment of the evidence, Annals of Pharmacotherapy, 39, 508, 10.1345/aph.1E398 Elvevag, 2000, Cognitive impairment in schizophrenia is the core of the disorder, Critical Review in Neurobiology, 14, 1, 10.1615/CritRevNeurobiol.v14.i1.10 Faul, 2007, G⁎power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences, Behavior Research Methods, 39, 175, 10.3758/BF03193146 Feldmann, 1995, Fragebogen zur erfassung der familienatmosphäre (fef): Einschätzung des emotionalen angehörigenverhaltens aus der sicht schizophrener patienten, Diagnostica, 41, 334 Fenton, 1997, Determinants of medication compliance in schizophrenia: empirical and clinical findings, Schizophrenia Bulletin, 23, 637, 10.1093/schbul/23.4.637 First, 1998 Fleischhacker, 2003, Factors influencing compliance in schizophrenia patients, Journal of Clinical Psychiatry, 64, S10 Franke, 1995 Garber, 2004, The concordance of self-report with other measures of medication adherence: a summary of the literature, Medical Care, 42, 649, 10.1097/01.mlr.0000129496.05898.02 Gray, 2006, Adherence therapy for people with schizophrenia, British Journal of Psychiatry, 189, 508, 10.1192/bjp.bp.105.019489 Guy, 1976 Haro, 2003, The clinical global impression-schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia, Acta Psychiatrica Scandinavica, 107, 16, 10.1034/j.1600-0447.107.s416.5.x Harrison, 2001, Recovery from psychotic illness: a 15- and 25-year international follow-up study, British Journal of Psychiatry, 178, 506, 10.1192/bjp.178.6.506 Heinrichs, 1984, The quality of life scale: an instrument for rating the schizophrenic deficit syndrome, Schizophrenia Bulletin, 10, 388, 10.1093/schbul/10.3.388 Higgins, 2011, The cochrane collaboration׳s tool for assessing risk of bias in randomised trials, British Medical Journal, 343, 10.1136/bmj.d5928 Hogan, 1983, A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity, Psychological Medicine, 13, 177, 10.1017/S0033291700050182 Hollingshead, 1958 Horne, 1999, Patients׳ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness, Journal of Psychosomatic Research, 47, 555, 10.1016/S0022-3999(99)00057-4 Huang, 2009, Medication compliance in outpatients with schizophrenia in one veterans hospital in taiwan, Journal of Food and Drug Analysis, 17, 401 Jones, 2006, Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study (cutlass 1), Archives of General Psychiatry, 63, 1079, 10.1001/archpsyc.63.10.1079 Jonsdottir, 2013, Predictors of medication adherence in patients with schizophrenia and bipolar disorder, Acta Psychiatrica Scandinavica, 127, 23, 10.1111/j.1600-0447.2012.01911.x Julius, 2009, Medication adherence: a review of the literature and implications for clinical practice, Journal of Psychiatric Practice, 15, 34, 10.1097/01.pra.0000344917.43780.77 Jung, 2002, A validation study of korean-version of liverpool university neuroleptic side effect rating scale (LUNSERS), Journal of the Korean Neuropsychiatric Association, 41, 138 Junghan, 2007, Staff and patient perspectives on unmet need and therapeutic alliance in community mental health services, British Journal of Psychiatry, 191, 543, 10.1192/bjp.bp.107.037978 Kahn, 2008, Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial, The Lancet, 371, 1085, 10.1016/S0140-6736(08)60486-9 Kamali, 2006, A prospective evaluation of adherence to medication in first episode schizophrenia, European Psychiatry, 21, 29, 10.1016/j.eurpsy.2005.05.015 Karow, 2007, Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia, Journal of Clinical Psychiatry, 68, 75, 10.4088/JCP.v68n0110 Kay, 1987, The positive and negative syndrome scale (PANSS) for schizophrenia, Schizophrenia Bulletin, 13, 261, 10.1093/schbul/13.2.261 Keefe, 2003, Neurocognitive assessment in the clinical antipsychotic trials of intervention effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale, Schizophrenia Bulletin, 29, 45, 10.1093/oxfordjournals.schbul.a006990 Keefe, 2007, How should DSM-V criteria for schizophrenia include cognitive impairment?, Schizophrenia Bulletin, 33, 912, 10.1093/schbul/sbm046 Kelly, 1987, Utility of the health belief model in examining medication compliance among psychiatric outpatients, Social Science and Medicine, 25, 1205, 10.1016/0277-9536(87)90367-4 Kemp, 1996, Psychological predictors of insight and compliance in psychotic patients, British Journal of Psychiatry, 169, 444, 10.1192/bjp.169.4.444 Kemp, 1996, Psychological predictors of insight and compliance in psychotic patients, British Journal of Psychiatry, 169, 444, 10.1192/bjp.169.4.444 Kessler, 1998, The cognitive appraisal of health scale: development and psychometric evaluation, Research in Nursing and Health, 21, 73, 10.1002/(SICI)1098-240X(199802)21:1<73::AID-NUR8>3.0.CO;2-Q Kikkert, 2008, Assessment of medication adherence in patients with schizophrenia: the achilles heel of adherence research, Journal of Nervous and Mental Disorders, 196, 274, 10.1097/NMD.0b013e31816a4346 Kikkert, 2011, The predictive validity of subjective adherence measures in patients with schizophrenia, International Journal of Methods in Psychiatric Research, 20, 73, 10.1002/mpr.335 Kim, 2012, Long-acting injectable antipsychotics for first-episode schizophrenia: the pros and cons, Schizophrenia Research and Treatment, 2012, 8, 10.1155/2012/560836 Kim, 2004, Assessing the reliability and validity of the korean version of the revised insight scale for psychosis (KISP), Schizophrenia Clinics, 7, 15 Klingberg, 2008, Collaboration in outpatient antipsychotic drug treatment: analysis of potentially influencing factors, Psychiatry Research, 161, 225, 10.1016/j.psychres.2007.07.027 Lacro, 2002, Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature, Journal of Clinical Psychiatry, 63, 892, 10.4088/JCP.v63n1007 Lanouette, 2009, Psychotropic medication nonadherence among united states latinos: a comprehensive literature review, Psychiatr Services, 60, 157, 10.1176/ps.2009.60.2.157 Lehman, 1988, A quality of life interview for the chronically mentally ill, Evaluation and Program Planning, 11, 51, 10.1016/0149-7189(88)90033-X Lepage, 2010, Is there an association between neurocognitive performance and medication adherence in first episode psychosis?, Early Intervention in Psychiatry, 4, 189, 10.1111/j.1751-7893.2010.00174.x Leucht, 2009, Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis, The Lancet, 373, 31, 10.1016/S0140-6736(08)61764-X Lieberman, 2003, Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine, Neuropsychopharmacology, 28, 995, 10.1038/sj.npp.1300157 Lieberman, 2003, Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol, American Journal of Psychiatry, 160, 1396, 10.1176/appi.ajp.160.8.1396 Lincoln, 2007, Correlates and long-term consequences of poor insight in patients with schizophrenia. A systematic review, Schizophrenia Bulletin, 33, 1324, 10.1093/schbul/sbm002 Linden, 1988, Zur definition, bedeutung und messung der krankheitskonzepte von patienten: Die krankheitskonzeptskala (kk-skala) für schizophrene patienten, Fortschritte der Neurologie—Psychiatrie, 56, 35, 10.1055/s-2007-1001215 Lingjærde, 1987, The uku side effect rating scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients, Acta Psychiatrica Scandinavica, 76, 1, 10.1111/j.1600-0447.1987.tb10566.x Magaña, 1986, A brief method for assessing expressed emotion in relatives of psychiatric patients, Psychiatry Research, 17, 203, 10.1016/0165-1781(86)90049-1 Malla, 2006, Predictors of rate and time to remission in first-episode psychosis: a two-year outcome study, Psychological Medicine, 36, 649, 10.1017/S0033291706007379 Marder, 2003, Overview of partial compliance, Journal of Clinical Psychiatry, 64, S3 Masand, 2009, Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review, Primary Care Companion to the Journal of Clinical Psychiatry, 11, 147, 10.4088/PCC.08r00612 McCabe, 2012, The therapeutic relationship and adherence to antipsychotic medication in schizophrenia, PLoS One, 7, e36080, 10.1371/journal.pone.0036080 McEvoy, 1989, Insight in schizophrenia. Its relationship to acute psychopathology, Journal of Nervous and Mental Disorders, 177, 43, 10.1097/00005053-198901000-00007 McEvoy, 2006, Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment, The American Journal of Psychiatry, 163, 600, 10.1176/ajp.2006.163.4.600 McIntosh, 2006, Compliance therapy for schizophrenia, Cochrane Database of Systematic Reviews, 3, CD003442 Meier, 2010, Effect of medication-related factors on adherence in people with schizophrenia: a european multi-centre study, Epidemiologia e Psichiatria Sociale, 19, 251, 10.1017/S1121189X00001184 Meier, 2010, Effect of medication-related factors on adherence in people with schizophrenia: a european multi-centre study, Epidemiologia e Psichiatria Sociale, 19, 251, 10.1017/S1121189X00001184 Miller, 2009, A prospective study of cannabis use as a risk factor for non-adherence and treatment dropout in first-episode schizophrenia, Schizophrenia Research, 113, 138, 10.1016/j.schres.2009.04.018 Misdrahi, 2012, The influence of therapeutic alliance and insight on medication adherence in schizophrenia, Nordic Journal of Psychiatry, 66, 49, 10.3109/08039488.2011.598556 Mohamed, 2009, Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia, Schizophrenia Bulletin, 35, 336, 10.1093/schbul/sbn067 Morisky, 1986, Concurrent and predictive validity of a self-reported measure of medication adherence, Medical Care, 24, 67, 10.1097/00005650-198601000-00007 Morken, 2007, Effects of integrated treatment on antipsychotic medication adherence in a randomized trial in recent-onset schizophrenia, Jounal of Clinical Psychiatry, 68, 566, 10.4088/JCP.v68n0409 Morken, 2008, Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia, BMC Psychiatry, 8, 32, 10.1186/1471-244X-8-32 Mullins, 2008, Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia, Schizophrenia Research, 98, 8, 10.1016/j.schres.2007.04.035 Mutsatsa, 2003, Clinical correlates of early medication adherence: West London first episode schizophrenia study, Acta Psychiatrica Scandinavica, 108, 439, 10.1046/j.0001-690X.2003.00193.x Naber, 1995, A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables, International Clinical Psychopharmacology, 10, S133 Naber, 2001, Improvement of schizophrenic patients׳ subjective well-being under atypical antipsychotic drugs, Schizophrenia Research, 50, 79, 10.1016/S0920-9964(00)00166-3 Norman, 2004, Understanding delay in treatment for first-episode psychosis, Psychological Medicine, 34, 255, 10.1017/S0033291703001119 Nosé, 2003, How often do patients with psychosis fail to adhere to treatment programmes? A systematic review, Psychological Medicine, 33, 1149, 10.1017/S0033291703008328 Novick, 2010, Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia, Psychiatry Research, 176, 109, 10.1016/j.psychres.2009.05.004 Oliver, 1997, Measuring the quality of life of severely mentally ill people using the lancashire quality of life profile, Socials Psychiatry and Psychiatric Epidemiology, 32, 76, 10.1007/BF00788924 Osterberg, 2005, Adherence to medication, New England Journal of Medicine, 353, 487, 10.1056/NEJMra050100 Perkins, 2006, Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode, Schizophrenia Research, 83, 53, 10.1016/j.schres.2005.10.016 Perkins, 2008, Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study, Journal of Clinical Psychiatry, 69, 106, 10.4088/JCP.v69n0114 Pinikahana, 2002, Exploring the complexity of compliance in schizophrenia Issues in mental health nursing, Issues in Mental Health Nursing, 23, 513, 10.1080/01612840290052677 Pomykacz, 2007, A review of brief medication-adherence instruments used in patients with schizophrenia and bipolar disorder, Harvard Review of Psychiatry, 15, 259, 10.1080/10673220701650383 Priebe, 1993, The role of the helping alliance in psychiatric community care. A prospective study, Journal of Nervous and Mental Disorders, 181, 552, 10.1097/00005053-199309000-00004 Quach, 2009, Predictors of poor adherence to medication among patients with first-episode schizophrenia-spectrum disorder, Early Intervention in Psychiatry, 3, 66, 10.1111/j.1751-7893.2008.00108.x Rabinovitch, 2009, Early predictors of nonadherence to antipsychotic therapy in first-episode psychosis, Canadian Journal of Psychiatry, 54, 28, 10.1177/070674370905400106 Remington, 2007, The use of electronic monitoring (MEMS®) to evaluate antipsychotic compliance in outpatients with schizophrenia, Schizophrenia Research, 90, 229, 10.1016/j.schres.2006.11.015 Reynolds, 2010, Metabolic side effects of antipsychotic drug treatment—pharmacological mechanisms, Pharmacology and Therapeutics, 125, 169, 10.1016/j.pharmthera.2009.10.010 Roberts, 2011, Medication adherence in schizophrenia, Drug Discovery Today: Therapeutic Strategies, 8, 11 Robinson, 2002, Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder, Schizophrenia Research, 57, 209, 10.1016/S0920-9964(01)00312-7 Rush, 1996, The inventory of depressive symptomatology (IDS): psychometric properties, Psychological Medicine, 26, 477, 10.1017/S0033291700035558 Sajatovic, 2010, Measurement of psychiatric treatment adherence, Journal of Psychosomatic Research, 69, 591, 10.1016/j.jpsychores.2009.05.007 Schulz, 2010, Consort 2010 statement: updated guidelines for reporting parallel group randomized trials, Annals of Internal Medicine, 152, 726, 10.7326/0003-4819-152-11-201006010-00232 Simpson, 1970, A rating scale for extrapyramidal side effects, Acta Psychiatrica Scandinavica, Supplement 212, S11, 10.1111/j.1600-0447.1970.tb02066.x Smith, 1992, Informing people with schizophrenia about their illness: the effect of residual symptoms, Journal of Mental Health, 1, 61, 10.3109/09638239209034512 Spitzer, 1978 Subotnik, 2011, Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia, American Journal of Psychiatry, 168, 286, 10.1176/appi.ajp.2010.09010087 Tait, 2002, A new scale (SES) to measure engagement with community mental health services, Journal of Mental Health, 11, 191, 10.1080/09638230020023570-2 Tranulis, 2011, Becoming adherent to antipsychotics: A qualitative study of treatment-experienced schizophrenia patients, Psychiatric Services, 62, 888, 10.1176/ps.62.8.pss6208_0888 Velligan, 2010, Methodological challenges in psychiatric treatment adherence research, Clinical Schizophrenia and Related Psychoses, 4, 74, 10.3371/CSRP.4.1.6 Velligan, 2006, Defining and assessing adherence to oral antipsychotics: a review of the literature, Schizophrenia Bulletin, 32, 724, 10.1093/schbul/sbj075 Velligan, 2007, Relationships among subjective and objective measures of adherence to oral antipsychotic medications, Psychiatric Services, 58, 1187, 10.1176/ps.2007.58.9.1187 Velligan, 2010, Assessment of adherence problems in patients with serious and persistent mental illness: recommendations from the expert consensus guidelines, Journal of Psychiatric Practice, 16, 34, 10.1097/01.pra.0000367776.96012.ca Velligan, 2009, The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness, Journal of Clinical Psychiatry, 70, S1, 10.4088/JCP.7090su1cj Ventura, 1993, Training and quality assurance with the brief psychiatric rating scale: “The drift busters”, International Journal of Methods in Psychiatric Research, 3, 221 von Elm, 2007, The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies, Bulletin of the World Health Organization, 85, 867, 10.2471/BLT.07.045120 Voruganti, 2008, New generation antipsychotic drugs and compliance behaviour, Current Opinion in Psychiatry, 21, 133, 10.1097/YCO.0b013e3282f52851 Wechsler, 1997 Wechsler, 1997 Weiden, 2007, Understanding and addressing adherence issues in schizophrenia: From theory to practice, Journal of Clinical Psychiatry, 68, 14 Weiden, 1997, The road back: working with the severely mentally ill. Medication noncompliance in schizophrenia: I. Assessment, Journal of Practical Psychiatry and Behavioral Health, 3, 106 West, 2002, 1 Yang, 2012, Symptom severity and attitudes toward medication: impacts on adherence in outpatients with schizophrenia, Schizophrenia Research, 134, 226, 10.1016/j.schres.2011.11.008 Young, 1978, A rating scale for mania: reliability, validity and sensitivity, British Journal of Psychiatry, 133, 429, 10.1192/bjp.133.5.429 Zygmunt, 2002, Interventions to improve medication adherence in schizophrenia, American Journal of Psychiatry, 159, 1653, 10.1176/appi.ajp.159.10.1653